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We previously showed that the mitogen-activated protein (MAP) kinase superfamily, p44/p42 MAP kinase, p38 MAP kinase, and
stress-activated protein kinase (SAPK)/c-Jun N-terminal (JNK), positively plays a part in the platelet-derived growth factor-BB-
(PDGF-BB-) stimulated synthesis of interleukin-6 (IL-6), a potent bone resorptive agent, in osteoblast-like MC3T3-E1 cells while
Akt and p70 S6 kinase negatively regulates the synthesis. In the present study, we investigated whether (-)-epigallocatechin gallate
(EGCG), one of the major green tea ﬂavonoids, aﬀects the synthesis of IL-6 in these cells and the mechanism. EGCG signiﬁcantly
reduced the IL-6 synthesis and IL-6 mRNA expression stimulated by PDGF-BB, EGCG reduced the PDGF-BB-stimulated IL-6
synthesis also in primary-cultured osteoblasts. EGCG had no eﬀect on the levels of osteocalcin and osteoprotegerin in MC3T3-E1
cells. The PDGF-BB-induced autophosphorylation of PDGF receptor β was not suppressed by EGCG. The PDGF-BB-induced
phosphorylation of p44/p42 MAP kinase and p38 MAP kinase was not aﬀected by EGCG. On the other hand, EGCG markedly
suppressedthePDGF-BB-inducedphosphorylationofSAPK/JNK.Finally,thePDGF-BB-inducedphosphorylationofAktandp70
S6 kinase was not aﬀected by EGCG. These results strongly suggest that EGCG inhibits the PDGF-BB-stimulated synthesis of IL-6
via suppression of SAPK/JNK pathway in osteoblasts.
Copyright © 2008 Shinji Takai et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Interleukin-6 (IL-6) is a multifunctional cytokine that has
important physiological eﬀects on a wide range of functions
such as promoting B-cell diﬀerentiation, T-cell activation,
and inducing acute phase proteins [1–4]. It is generally rec-
ognized that two functional cells, osteoblasts and osteoclasts,
strictly regulate bone metabolism, the former responsible for
bone formation and the latter for bone resorption [5]. The
formation of bone structures and bone remodeling results
from the coupling process; bone resorption by activated
osteoclasts with subsequent deposition of new matrix by
osteoblasts. In bone metabolism, it is well recognized that
IL-6 is one of the most potent osteoclastogenic factors
[3, 4]. Bone resorption is mediated by the increased
local production of inﬂammatory cytokines such as tumor
necrosis factor-α and IL-1. In osteoblasts [6–8], it has been
reported that bone resorptive agents such as tumor necrosis
factor-α and IL-1 stimulate the synthesis of IL-6. As for
bone metabolism, IL-6 has been shown to stimulate bone
resorption and induce osteoclast formation [3, 4, 7, 9]. Thus,
accumulating evidence indicates that IL-6 secreted from
osteoblasts plays a key role as a downstream eﬀector of bone
resorptive agents. It has been shown that platelet-derived
growth factor-BB (PDGF-BB), a well-known mitogenic
factor, increases proliferation and inhibits the diﬀerentiation
of osteoblasts [10]. PDGF-BB also enhances bone resorption
by increasing the number of osteoclasts, an eﬀect that may
be secondary to an increase in the expression of IL-6 [10,
11]. Therefore, modulation of PDGF-BB eﬀect would be2 Mediators of Inﬂammation
a possible therapeutic target of osteoporosis. In our recent
studies [12, 13], we have reported that PDGF-BB stimulates
IL-6 synthesis through p44/p42 MAP kinase, p38 MAP
kinase, and stress-activated protein kinase (SAPK)/c-Jun N-
terminal (JNK), members of the MAP kinase superfamily
[14], in osteoblast-like MC3T3-E1 cells and that Akt and p70
S6kinaselimitsthesynthesis.However,theexactmechanism
of PDGF-BB underlying the IL-6 synthesis in osteoblasts has
not yet been elucidated.
Compounds in foods such as vegetables and fruits
have beneﬁcial properties to human being. Among them,
it has been reported that ﬂavonoids possess antioxidative,
antibacterial, and antitumor eﬀects [15, 16]. Catechins are
one of the major ﬂavonoids, which are present in various
species of plants such as green tea [16]. In bone metabolism,
it has been shown that catechin suppresses bone resorption
[17]. As for osteoclasts, it has been reported that (−)-
epigallocatechingallate(EGCG)inducesosteoclastapoptosis
[18,19]andsuppressesthediﬀerentiation[20].However,the
eﬀects of EGCG on the expression of cytokines or matrix-
degrading enzyme from osteoclast-stimulated or treated
o s t e o b l a s t i cc e l l sh a v en o tb e e nr e p o r t e da sf a ra sw ek n o w .
As for osteoblasts, it has been shown that catechin stimulates
alkaline phosphatase activity, a mature osteoblast phenotype
[5], and reduces apoptosis in osteoblast-like MC3T3-E1
cells [21]. However, the exact mechanism of catechin in
osteoblasts is not fully known.
In the present study, we investigated whether (−)-
epigallocatechin gallate (EGCG), one of the major green tea
ﬂavonoids, aﬀects the PDGF-BB-stimulated IL-6 synthesis
in osteoblast-like MC3T3-E1 cells and the mechanism
behind it. We here show that EGCG reduces the PDGF-
BB-stimulated IL-6 synthesis via attenuation of SAPK/JNK
pathway in these cells.
2. MATERIALS AND METHODS
2.1. Materials
Recombinant PDGF-BB, IL-6 ELISA, osteocalcin ELISA,
and osteoprotegerin (OPG) ELISA kit were purchased from
R&D Systems, Inc. (Minneapolis, Minn, USA). EGCG was
obtained from Calbiochem-Novabiochem Corp. (La Jolla,
Calif, USA). Phospho-speciﬁc PDGF receptor β antibodies,
PDGF receptor β antibodies, phospho-speciﬁc p44/p42
MAP kinase antibodies, p44/p42 MAP kinase antibodies,
phospho-speciﬁc p38 MAP kinase antibodies, p38 MAP
kinase antibodies, phospho-speciﬁc SAPK/JNK kinase anti-
bodies, SAPK/JNK antibodies, phospho-speciﬁc Akt anti-
bodies, Akt antibodies, phospho-speciﬁc p70 S6 kinase
antibodies, and p70 S6 kinase antibodies were purchased
from Cell Signaling Technology (Beverly, Mass, USA). ECL
Western blotting detection system was purchased from
Amersham Japan (Tokyo, Japan). Other materials and chem-
icals were obtained from commercial sources.
2.2. Cellculture
The cloned osteoblast-like MC3T3-E1 cells, which have been
derivedfromnewbornmousecalvaria[22], were maintained
as previously described [23]. Brieﬂy, the cells were cultured
in α-minimum essential medium (α-MEM) containing 10%
fetal calf serum (FCS) at 37◦C in a humidiﬁed atmosphere of
5% CO2/95% air. The cells were seeded into 35mm diameter
dishes(5×104/dish)or90mmdiameterdishes(5×105/dish)
in α-MEM containing 10% FCS. After 5 days, the medium
was exchanged for α-MEM containing 0.3% FCS. The cells
were used for experiments after 48 hours.
Primary-cultured osteoblasts were obtained from the
calvaria of newborn (1 or 2-day old) balb/c mice as
previously described [24]. They were seeded into 90mm
diameter dishes (25 × 104 cells) in α-MEM containing 10%
FCS. The medium was changed every 3 days until the
cells reached conﬂuence at 5 days. Then, the medium was
exchanged for α-MEM containing 0.3% FCS. The cells were
used for experiments after 48 hours.
2.3. Assaysforosteocalcin,OPG,andIL-6
The cultured cells were pretreated with vehicle or various
doses of EGCG (1 to 30μM) for 24 hours, the levels of
osteocalcin and OPG in the medium were measured by
respective ELISA kit. The cultured cells were stimulated by
PDGF-BB in 1mL of α-MEM containing 0.3% FCS, and
then incubated for the indicated periods. The conditioned
medium was collected, and IL-6 in the medium was then
measured by IL-6 ELISA kit. When indicated, the cells were
pretreated with various doses of EGCG for 60 minutes.
2.4. Real-timeRT-PCR
The cultured cells were pretreated with 30μME G C Go r
vehicle for 60 minutes, and then stimulated by 50ng/mL
PDGF-BB for 60 minutes. Total RNA was isolated and
transcribed into complementary DNA using Trizol reagent
and Omniscript Reverse Transcriptase Kit. Real-time RT-
PCR was performed using a Light Cycler system (Roche
Diagnostics Basel, Switzerland) in capillaries and FastStart
DNA Master SYBR Green I provided with the kit. Sense
and antisense primers were synthesized based on the report
of Simpson et al.for mouse GAPDH mRNA [25]. Sense
and antisense primers for mouse IL-6 mRNA were pur-
chased from Takara Bio Inc. (Tokyo, Japan) (primer set
ID:MA039013). The ampliﬁed products were determined
by melting curve analysis and agarose electrophoresis. IL-6
mRNAlevelswerenormalizedwiththoseofGAPDHmRNA.
2.5. Analysisofwesternblotting
The cultured cells were stimulated by PDGF-BB in α-MEM
containing0.3%FCSfortheindicatedperiods.Thecellswere
washed twice with phosphate-buﬀered saline and then lysed,
homogenized, and sonicated in a lysis buﬀer containing
62.5mM Tris/HCl, pH 6.8, 2% sodium dodecyl sulfate
(SDS),50mMdithiothreitol,and10%glycerol.Thecytosolic
fraction was collected as a supernatant after centrifugation
at 125,000×gf o r1 0m i n u t e sa t4 ◦C. SDS-polyacrylamide
gel electrophoresis (PAGE) was performed by Laemmli [26]
in 10% polyacrylamide gel. Western blotting analysis wasShinji Takai et al. 3
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Figure 1: Eﬀect of EGCG on the PDGF-BB-stimulated IL-6 synthesis and expression levels of IL-6 mRNA in osteoblasts. (a) Osteoblast-like
MC3T3-E1 cells were pretreated with various doses of EGCG for 60 minutes, and then stimulated by 50ng/mL PDGF-BB or vehicle for 24
hours. Each value represents the mean ± SEM of triplicate determinations. Similar results were obtained with two additional and diﬀerent
cell preparations. ∗P<. 05: compared to the value of control. ∗∗P<. 05: compared to the value of PDGF-BB alone. (b) Primary cultures
of osteoblast were pretreated with or without 30μMo fE G C Gf o r6 0m i n u t e s ,a n dt h e ns t i m u l a t e db y5 0n g / m LP D G F - B Bo rv e h i c l ef o r2 4
hours. Each value represents the mean ± SEM of triplicate determinations. Similar results were obtained with two additional and diﬀerent
cell preparations. ∗P<. 05: compared to value of the PDGF-BB alone. (c) Osteoblast-like MC3T3-E1 cells were pretreated with 30μM
EGCG or vehicle for 60 minutes, and then stimulated by 50 ng/mL PDGF-BB for 60 minutes. Total RNA was isolated and transcribed into
complementary DNA. The expressions of IL-6 mRNA and GAPDH mRNA were quantiﬁed by real-time RT-PCR. IL-6 mRNA levels were
normalized with those of GAPDH mRNA. Results were standardized for the value of control (without EGCG and PDGF-BB). Each value
represents the mean ± SEM of triplicate determinations. Similar results were obtained with two additional and diﬀerent cell preparations.
∗P<. 05: compared to the value of control. ∗∗P<. 05: compared to the value of PDGF-BB alone.
performed as described previously [27] by using phospho-
speciﬁc PDGF receptor β antibodies, PDGF receptor β
antibodies, phospho-speciﬁc p44/p42 MAP kinase anti-
bodies, p44/p42 MAP kinase antibodies, phospho-speciﬁc
p38 MAP kinase antibodies, p38 MAP kinase antibodies,
phospho-speciﬁc SAPK/JNK kinase antibodies, SAPK/JNK
antibodies, phospho-speciﬁc Akt antibodies, Akt antibodies,
phospho-speciﬁc p70 S6 kinase antibodies, and p70 S6
kinase antibodies with peroxidase-labeled antibodies raised
in goat against rabbit IgG being used as second antibodies.4 Mediators of Inﬂammation
Peroxidase activity on PVDG membrane was visualized on
X-ray ﬁlm by means of the ECL Western blotting detection
system. When indicated, the cells were pretreated with
various doses of EGCG for 60 minutes.
2.6. Determinations
T h ea b s o r b a n c eo fe n z y m ei m m u n o a s s a ys a m p l e sw a sm e a -
sured at 450nm with EL 340 Bio Kinetic Reader (Bio-Tek
Instruments, Inc., Winooski, Vt, USA). The densitometric
analysis was performed using Molecular Analyst/Macintosh
(Bio-Rad Laboratories, Hercules, Calif, USA).
2.7. Statisticalanalysis
The data were analyzed by ANOVA followed by the Bonfer-
roni method for multiple comparisons between pairs, and a
P<. 05 was considered signiﬁcant. All data are presented
as the mean ± SEM of triplicate determinations. Each
experiment was repeated three times with similar results.
3. RESULTS
3.1. EffectsofEGCGonthePDGF-BB-stimulatedIL-6
synthesisinMC3T3-cellsandprimary-cultured
mouseosteoblasts
It has been reported that PDGF-BB induces transcription
of IL-6 in rat osteoblasts [11]. We have previously found
thatPDGF-BBstimulatesIL-6synthesisinmouseosteoblast-
like MC3T3-E1 cells [12]. We ﬁrst examined the eﬀect of
EGCG on the PDGF-BB-stimulated IL-6 synthesis. EGCG,
which alone had little eﬀect on the IL-6 levels, signiﬁ-
cantly reduced the PDGF-BB-stimulated synthesis of IL-6
(Figure 1(a)). EGCG (30μM) caused about 50% reduction
in the PDGF-BB eﬀect. In addition, we also examined
the eﬀect of EGCG in primary-cultured mouse osteoblasts.
PDGF-BB signiﬁcantly enhanced IL-6 synthesis in primary
osteoblasts (Figure 1(b)). Furthermore, EGCG (30μM) sig-
niﬁcantly reduced the PDBF-BB-stimulated synthesis of IL-6
(Figure 1(b)). We next assessed the eﬀect of EGCG on cell
viability by trypan blue dye exclusion test. We conﬁrmed
that the viability of MC3T3-E1 cells incubated at 37◦Cf o r
24 hours in the presence of 30μM EGCG was more than
90% in comparison to that of the control cells. To determine
whetherEGCGcouldaﬀectthecellproliferation,wecounted
thecellnumberbeforeandafterthe24-hourincubationwith
30μM EGCG. We conﬁrmed that EGCG did not aﬀect the
cell number at a dose of 30μM( 9 .7 ± 1.1 × 105 cells/mL for
control;9.1±1.6×105 cells/mLfor30μMEGCGasmeasured
during the stimulation for 24 hours). Therefore, EGCG at
30μMh a r d l ya ﬀects the cell viability or proliferation of
osteoblast-like MC3T3-E1 cells up to 24 hours.
3.2. EffectsofEGCGonthelevelsofosteocalcinand
osteoprotegerininMC3T3-E1-cells
Next, to determine whether EGCG aﬀects the diﬀerentiation
of these cells, we examined the eﬀect of EGCG on the
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Figure 2: Eﬀect of EGCG on the PDGF-BB-induced autophos-
p h o r y l a t i o no fP D G Fr e c e p t o rβ in MC3T3-E1 cells. The cultured
cells were pretreated with the indicated doses of EGCG or vehicle
for 60 minutes, and then stimulated by 50ng/mL PDGF-BB or
vehicle for 3 minutes. The extracts of cells were subjected to SDS-
PAGE with subsequent Western blotting analysis with antibodies
against phospho-speciﬁc PDGF receptor β or PDGF receptor β.
The histogram shows quantitative representations of the levels
of PDGF-BB-induced autophosphorylation obtained from laser
densitometric analysis of three independent experiments. Each
value represents the mean ± SEM of triplicate determinations.
Similar results were obtained with two additional and diﬀerent cell
preparations.
synthesis of osteocalcin, a mature osteoblast phenotype [28],
and osteoprotegerin (OPG), produced by osteoblasts and
inhibiting osteoclastic bone resorption [29], synthesis in
MC3T3-E1 cells. We found that EGCG had no eﬀect on the
osteocalcin(notdetectableundertheexperimentalcondition
at all; <1.56 ng/mL) and OPG (1967 ± 34pg/mL for vehicle;
1846 ± 46pg/mL with 30μM of EGCG) synthesis.
3.3. EffectofEGCGonthePDGF-BB-induced
expressionlevelsofIL-6mRNAin
MC3T3-E1cells
To clarify whether the suppressive eﬀect by EGCG of
PDGF-BB-stimulated IL-6 synthesis is mediated through
transcriptionaleventornot,weexaminedtheeﬀectofEGCG
on the PDGF-BB-induced IL-6 mRNA expression by real-
time RT-PCR. We found that EGCG (30μM) signiﬁcantly
downregulated the IL-6 mRNA expression levels 60 min-
utes after the stimulation (Figure 1(c)), suggesting that the
suppressive eﬀect of EGCG is mediated at least in part by
the reduction of IL-6 synthesis in osteoblast-like MC3T3-E1
cells.Shinji Takai et al. 5
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Figure 3: Eﬀect of EGCG on the phosphorylation of p44/p42 MAP kinase and p38 MAP kinase induced by PDGF-BB in MC3T3-E1 cells.
The cultured cells were pretreated with the indicated doses of EGCG or vehicle for 60 minutes, and then stimulated by 50ng/mL PDGF-BB
or vehicle for 3 minutes. The extracts of cells were subjected to SDS-PAGE with subsequent Western blotting analysis with antibodies against
(a) phospho-speciﬁc p44/p42 MAP kinase or p44/p42 MAP kinase, and (b) phospho-speciﬁc p38 MAP kinase or p38 MAP kinase. The
histogram shows quantitative representations of the levels of PDGF-BB-induced phosphorylation obtained from laser densitometric analysis
of three independent experiments. Each value represents the mean ± SEM of triplicate determinations. Similar results were obtained with
two additional and diﬀerent cell preparations.
3.4. EffectofEGCGonthePDGF-BB-induced
autophosphorylationofPDGFreceptor
βinMC3T3-E1cells
InordertoclarifytheinhibitorymechanismofEGCGbehind
the PDGF-BB-stimulated IL-6 synthesis in these cells, we
next examined the eﬀect of EGCG on the PDGF-BB-induced
autophosphorylation of PDGF receptor β. EGCG failed to
aﬀect the PDGF-BB-induced autophosphorylation of PDGF
receptor β (Figure 2). These results lead us to speculate that
the mechanism of EGCG-eﬀect on the PDGF-BB-stimulated
IL-6 synthesis may be mediated through downstream of
PDGF receptor activation.
3.5. EffectsofEGCGonthePDGF-BB-induced
phosphorylationofp44/p42MAPkinase,p38
MAPkinase,orSAPK/JNKinMC3T3-E1cells
In our previous study [13], we reported that PDGF-BB
activates three major MAP kinases, p44/p42 MAP kinase,
p38 MAP kinase, and SAPK/JNK, resulting in the synthesis
of IL-6 in MC3T3-E1 cells. We next examined the eﬀect
of EGCG on the PDGF-BB-induced phosphorylation of
p44/p42MAPkinase,p38MAPkinase,orSAPK/JNK.EGCG
failed to aﬀect the PDGF-BB-induced phosphorylation of
p44/p42 MAP kinase or p38 MAP kinase (Figures 3(a)
and 3(b)). On the contrary, EGCG, which by itself had
little eﬀect on the phosphorylation levels of SAPK/JNK,
signiﬁcantly suppressed the PDGF-BB-induced SAPK/JNK
phosphorylation (Figure 4). According to the densitometric
analysis, EGCG (30μM) caused about 40% reduction in the
PDGF-BB-eﬀect.
3.6. EffectsofEGCGonthePDGF-BB-induced
phosphorylationofAktorp70S6kinase
inducedbyPDGF-BBinMC3T3-E1cells
In our previous studies [12, 13], we demonstrated that
the PDGF-BB-activated Akt and p70 S6 kinase limit the
synthesis of IL-6 in MC3T3-E1 cells. In order to investigate
whether EGCG-eﬀect on the PDGF-BB-stimulated IL-6
synthesis is mediated via the activation of Akt or p70 S6
kinase in these cells, we examined the eﬀect of EGCG on
the PDGF-BB-induced phosphorylation of Akt or p70 S6
kinase. However, EGCG had little eﬀect on the PDGF-BB-
induced phosphorylation of Akt (Figure 5(a)) or p70 S6
kinase (Figure 5(b)).
4. DISCUSSION
In the present study, we showed that EGCG signiﬁcantly
suppressed the PDGF-BB-stimulated IL-6 synthesis and6 Mediators of Inﬂammation
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Figure 4: Eﬀe c to fE G C Go nt h ep h o s p h o r y l a t i o no fS A P K / J N K
induced by PDGF-BB in MC3T3-E1 cells. The cultured cells were
pretreated with the indicated doses of EGCG or vehicle for 60
minutes, and then stimulated by 50ng/mL PDGF-BB or vehicle
for 3 minutes. The extracts of cells were subjected to SDS-PAGE
with subsequent Western blotting analysis with antibodies against
phospho-speciﬁc SAPK/JNK or SAPK/JNK. The histogram shows
quantitative representations of the levels of PDGF-BB-induced
phosphorylationobtainedfromlaserdensitometricanalysisofthree
independent experiments. Each value represents the mean ± SEM
of triplicate determinations. Similar results were obtained with two
additional and diﬀerent cell preparations. ∗P<. 05: compared to
the value of PDGF-BB alone.
expression levels of IL-6 mRNA in osteoblast-like MC3T3-
E1 cells. We found that EGCG reduced the PDGF-BB-
stimulated IL-6 synthesis also in primary-cultured mouse
osteoblasts. These ﬁndings suggest that the inhibitory eﬀect
of EGCG on the PDGF-BB-stimulated IL-6 synthesis is not
speciﬁc in a clonal osteoblast-like MC3T3-E1 cells but it is
common in osteoblasts. We conﬁrmed that EGCG at 30μM
hardly aﬀects the cell viability or proliferation of osteoblast-
like MC3T3-E1 cells up to 24 hours. As for the eﬀects of
EGCGonthediﬀerentiationofthesecells,theresultsshowed
thatEGCGhadnoeﬀectontheosteocalcinandOPGsynthe-
sis. However, it has been shown that catechin stimulates the
alkaline phosphatase activity, a mature osteoblast phenotype
[5], and reduces bone-resorptive cytokine production in
osteoblast-like MC3T3-E1 cells [21]. Taking these results
into account, it is suggested that EGCG can partially aﬀect
the diﬀerentiation of osteoblast-like MC3T3-E1 cells. We
next investigated the mechanism of EGCG underlying the
inhibitory eﬀect on the IL-6 synthesis. It is well known that
the MAP kinase superfamily plays a crucial role in cellular
functions including proliferation, diﬀerentiation, and sur-
vival in a variety of cells [14]. Three major MAP kinases,
p44/p42 MAP kinase, p38 MAP kinase, and SAPK/JNK,
are known as central elements used by mammalian cells
to transduce the diverse messages [14]. We have previously
r e p o r t e dt h a tS A P K / J N Ka c ta sp o s i t i v er e g u l a t o r si nP D G F -
BB-induced IL-6 synthesis in MC3T3-E1 cells [13]. In the
present study, we showed that EGCG did not aﬀect the
PDGF-BB-induced phosphorylation of p44/p42 MAP kinase
or p38 MAP kinase. Therefore, it seems unlikely that EGCG
reduces the PDGF-BB-stimulated IL-6 synthesis through
downregulating activation of p44/p42 MAP kinase or p38
MAP kinase in osteoblast-like MC3T3-E1 cells. On the other
hand, we showed that the PDGF-BB-induced phosphory-
lation of SAPK/JNK was markedly suppressed by EGCG.
These results suggest that EGCG downregulates the PDGF-
BB-stimulated activation of SAPK/JNK. Taking our ﬁndings
into account, it is most likely that EGCG inhibits PDGF-
BB-stimulated IL-6 synthesis through downregulating the
activation of SAPK/JNK in osteoblast-like MC3T3-E1 cells.
Further investigations are required to clarify the precise
mechanism of catechin underlying the suppression of IL-6
synthesis in osteoblasts.
We previously showed that Akt and p70 S6 kinase
negativelyregulatesthePDGF-BB-stimulatedsynthesisofIL-
6 in osteoblast-like MC3T3-E1 cells [12, 13]. We additionally
investigated the involvement of Akt and p70 S6 kinase in the
inhibitory eﬀect of EGCG on the IL-6 synthesis. However,
EGCG failed to aﬀect the PDGF-BB-induced phosphoryla-
tion of Akt or p70 S6 kinase. Therefore, it seems unlikely
that EGCG inhibits PDGF-BB-induced IL-6 synthesis via
downregulating the activation of Akt or p70 S6 kinase
in osteoblast-like MC3T3-E1 cells. Taking our ﬁndings
into account, it is most likely that EGCG inhibits PDGF-
BB-stimulated IL-6 synthesis through downregulating the
activation of SAPK/JNK in osteoblast-like MC3T3-E1 cells.
IL-6, which is synthesized from osteoblasts, modulates a
variety of bone cell function [3]. In bone metabolism, IL-
6 secreted from osteoblasts acts as an autocrine/paracrine
factor, which induces osteoclast formation and stimulates
its activity to resorb bone [4, 7]. Based on our results, it
is probable that catechin-induced suppression of SAPJ/JNK
activation by PDGF-BB has an inhibitory eﬀect on bone
resorption via downregulating IL-6 synthesis in osteoblasts.
It has been reported that PDGF-BB is recognized as a
potent stimulator of osteoblast proliferation and collagen
synthesis [30]. PDGF, released during platelet aggregation,
has a pivotal role in fracture healing as a systemic factor,
and that PDGF also regulates bone remodeling as a local
factor [30]. As for osteoporosis, one of the major problems
in the health of elderly persons in advanced countries, it
is reported that administration of recombinant PDGF-BB
accelerates fracture healing in the geriatric, osteoporotic rat
[31]. However, the present study indicates that PDBG-BB
stimulates IL-6 synthesis, one of the potent bone resorptive
agents, not only by osteoblast-like MC3T3-E1 cells but also
by cultured primary osteoblast. In the present study, note-
worthy, EGCG reduced PDGF-BB-stimulated IL-6 synthesis
in osteoblasts. Therefore, our present ﬁndings led us to
speculate that EGCG might enhance the fracture healing
properties of PDGF-BB by reducing the IL-6 synthesis inShinji Takai et al. 7
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Figure 5: Eﬀect of EGCG on the phosphorylation of Akt and p70 S6 kinase induced by PDGF-BB in MC3T3-E1 cells. The cultured cells
were pretreated with the indicated doses of EGCG or vehicle for 60 minutes, and then stimulated by 50ng/mL PDGF-BB or vehicle for 20
minutes. The extracts of cells were subjected to SDS-PAGE with subsequent Western blotting analysis with antibodies against (a) phospho-
speciﬁc Akt or Akt, and (b) phospho-speciﬁc p70 S6 kinase or p70 S6 kinase. The histogram shows quantitative representations of the levels
of PDGF-BB-induced phosphorylation obtained from laser densitometric analysis of three independent experiments. Each value represents
the mean ± SEM of triplicate determinations. Similar results were obtained with two additional and diﬀerent cell preparations.
osteoblasts. Our present data would provide a new insight
in pharmacological eﬀects of catechin on bone metabolism.
The pharmacokinetics of EGCG in human volunteers
taking single dosage of 1 600mg/day showed a rapid
absorption, with a maximum plasma concentration value
of 11.08μM( = 3392ng/mL); the time to reach maximum
plasma concentration was 2.2 hours, and the terminal
elimination half-life ranged between 1.9 and 4.6 hours [32].
Interestingly, 10-day repeated administration of oral doses
of EGCG of up to 800mg/day was found to be safe and
very well tolerated [33]. In the present study, we showed
that the signiﬁcant suppressive eﬀect of EGCG on the
PDGF-BB-stimulated IL-6 synthesis was clearly observed at
10μM. Therefore, it is most likely that one could drink
enough green tea to reach in vivo levels which are used
in our in vitro study. In addition, it has been shown that
the plasma concentration of EGCG required for cancer
prevention or anti-inﬂammatory eﬀects is over 10μMt o
50μM[ 34–36]. Our results, regarding suppression of IL-
6 synthesis, are consistent with these previous ﬁndings.
Little is known regarding the eﬀective concentration of
EGCG requiredto modulate intracellular signaling pathways.
Further investigations using primary-cultured osteoblasts in
addition to MC3T3-E1 cells would be necessary to elucidate
the exact roles of catechin in the bone metabolism.
In conclusion, our present results strongly suggest that
catechin inhibits the PDGF-BB-stimulated synthesis of IL-6
via suppression of SAPK/JNK pathway in osteoblasts.
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